-ICE regimen shortly after diagnosis to mobilize progenitor cells into the peripheral blood (PBPCs). The sex distribution was 12 males and eight females and the median (range) age 48.5 (22-62) years. The time interval between diagnosis and mobilization was a median (range) of 2 (0-5) months. Leukaphereses were initiated during recovery from chemotherapy-induced aplasia. A median number of 3 (1-7) aphereses per patient were performed to collect у2.0 ؋ 10 6 CD34 ؉ cells/kg. Cytogenetic analysis was performed on the aphereses products of 18 patients. Complete cytogenetic Ph chromosome negativity was observed in four patients, nine had a partial negativity, three a minimal negativity and two no negative cells. Southern blot for bcr-abl was negative in the remaining two patients but the polymerase chain reaction analysis was positive. Following reinfusion, severe neutropenia was present for a median of 8.5 (3-19) days and severe thrombocytopenia lasted a median of 8 (3-18) days. Ten patients did not develop febrile neutropenia with four of them being treated on an outpatient basis. Treatment-related mortality was not observed. In conclusion, our experience demonstrates the feasibility of mobilizing PBPCs shortly after the diagnosis of CML with a safe regimen. Of note, mini-ICE allowed the collection of apheresis products with at least a major component of Ph-negative cells in almost 75% of the patients. Keywords: chronic myelogenous leukaemia; mini-ICE regimen; peripheral blood progenitor cell mobilization; autologous transplantation Chronic myelogenous leukaemia (CML) is a clonal myeloproliferative disorder resulting from the transformation and expansion of haemopoietic stem cells which continue to differentiate into mature granulocytes, monocytes, red cells and platelets. The majority of patients with CML are ineli-
gible for allogeneic BMT, the only potentially curative therapy, since half of them are above 50 years of age, only 25-30% have an HLA-identical sibling donor and unrelated progenitor cell transplantation is an option for only a subset of patients. Another alternative in CML is IFN-␣ which has been reported to significantly prolong survival, basically in those patients achieving a major cytogenetic remission with this drug. [1] [2] [3] [4] Autologous progenitor cell transplantation (ASCT) is increasingly being investigated in patients lacking a HLA-matched donor and not responding to IFN-␣. Some authors have suggested that overall survival could be prolonged with this approach. 5 One of the problems facing ASCT is when and how to collect peripheral blood progenitor cells (PBPCs). The Genoa Group 6 was the first to demonstrate that Ph chromosome-negative (Ph−) progenitor cells could be harvested during recovery from aplasia induced by an intensive chemotherapy regimen (the ICE protocol), even in patients in blastic transformation. Further studies performed by the same group and others 7, 8 showed that the same regimen was able to yield Ph− cells in up to 60% of IFN-␣-resistant patients in chronic phase (CP) and in up to 30% of patients in accelerated phase (AP). Other groups using different chemotherapy regimens also achieved variable degrees of Ph negativity in the apheresis products of CML patients in CP. [9] [10] [11] [12] From these experiences, disease duration and previous treatment with IFN-␣ emerge as the most important factors influencing cytogenetic negativity in the apheresis products; the percentage of aphereses with major cytogenetic negativity seems substantially higher in recently diagnosed patients without IFN-␣ pretreatment. Nevertheless, some of these regimens are not devoid of substantial side-effects and the overall mortality rate is 5%. Recently, Carella et al 13 have shown in 19 CML patients at diagnosis that a less intensive chemotherapy regimen, the mini-ICE protocol, results in similar cytogenetic negativity in the apheresis products with significantly less toxicity than the ICE regimen. Here, we report our results with mini-ICE at diagnosis in 20 consecutive CML patients treated at two institutions in Barcelona.
Patients and methods

Patients
Eligible patients were those with Ph chromosome-positive (Ph+) CML in first CP lacking an HLA-identical sibling and aged between 18 and 65 years. Exclusion criteria were a Karnofsky performance status of р70% or signs of renal or liver failure (serum creatinine Ͼ132 mol/l or AST/ALT Ͼ2 times the normal value). Verbal informed consent was obtained from each individual before the start of mobilization therapy. Between April 1996 and May 1998, 20 consecutive patients were mobilized with the mini-ICE regimen to collect PBPCs at diagnosis. Clinical characteristics are shown in Table 1 . Twelve patients were treated at the Hospital de la Santa Creu i Sant Pau and the remaining eight at the Institut Català d'Oncologia. There were 12 males and eight females with a median (range) age of 48.5 (22-62) years. All the patients were in first CP and had 100% Ph+ metaphases in marrow cells examined by conventional cytogenetics, as a reflection of the typical chromosomal translocation t(9;22) (n = 19) or due to a complex chromosomal translocation t(2;9;22) (n = 1). Fourteen patients were in clinical stage I according to the Kantarjian classification, 14 five patients in stage II and one patient in stage III. Hydroxyurea was used in all patients as the only cytoreductive therapy before mobilization. The time interval between diagnosis and stem cell mobilization was a median of 2 (0-5) months. therapy-induced neutropenia in all patients and eight patients additionally received oral fluconazole 200 mg/day as antifungal prophylaxis. All patients were nursed in double rooms without strict isolation measures during hospital admission. In 10 cases pancytopenia was managed on an outpatient basis and six of them had to be admitted to the hospital for febrile neutropenia. Leukaphereses (у15 l) were performed using a CS3000 PLUS machine (Fenwall, Baxter Healthcare, Deerfield, IL, USA) or a COBE SPECTRA (COBE, Lakewood, CO, USA), starting when PB WBC reached 1.0 × 10 9 /l or CD34 + cells were more than 2.5 × 10 3 /ml. Aphereses were performed daily and continued until the total number of CD34 + cells collected was у2.0 × 10 6 /kg body weight.
Mobilization and harvest of PBPCs
Analysis of leukapheresis products
Each leukapheresis was assayed for the content of mononuclear cells (MNC), CD34 + cells and CFU-GM. Conventional cytogenetic analysis and molecular analysis by Southern blot and polymerase chain reaction (PCR) were also performed from each bag.
Immunophenotypic analysis of PBPCs: Differential blood counts in PB and leukapheresis products and total number of MNC in the leukapheresis products were analysed using a Coulter JT 3 counter (Coulter Electronic, Hialeah, FL, USA). The number of CD34 + cells present in peripheral blood (PB) and the harvested products were assessed by direct immunofluorescence (PE-8G12; Becton Dickinson, San José, CA, USA). Flow cytometry was performed on an EPICS-XL cytometer (Coulter Electronic) equipped with a 488 nm excitation Argon laser. Data (100-500 events of CD34 + cells per sample) were stored in list mode data file and analysed on an EPICS-XL software.
Colony assays: Clonogenic assays were performed using a commercially prepared methycellulose-based medium with rh-SCF, rhIL-3, rhGM-CSF and rh-erythropoietin (Stem Cell Technologies, Vancouver, Canada). Assays were run in triplicate. Cells were plated at 10 5 cells/ml, cultures were incubated at 37°C and 5% CO 2 and colonies were enumerated using an inverted microscopy after 10 days of culture.
Cytogenetic analysis of leukaphereses products: Cells were cultured for 24-48 h without stimulation. Chromosomes were banded using G-banding and, when available, at least 25 metaphases were analysed for each culture. The degree of cytogenetic negativity was established following the Houston criteria for response: 16 complete, 0-5% Ph+ metaphases; partial, 6-34% Ph+ metaphases; minimal, 35-94% Ph+ metaphases; none, 95-100% Ph+ metaphases. Major negativity was considered when Ͻ35% Ph+ metaphases were observed in the apheresis product (complete plus partial).
Molecular analysis of the apheresis products:
Genomic DNA and total cellular RNA were extracted from 10 7 MNC with phenol-chloroform by standard procedures. 17 For Southern blot analysis 10 g of DNA were digested with Bg/II restriction enzyme, electrophoresed on a 0.7% agarose gel, transferred to nylon fibers, and hybridized to the ␣-32 P-radiolabeled phl/bcr-3 probe (Oncogene Science). RT-PCR analysis was performed as previously described. 18 
Statistics
Results are expressed as median and range. Comparison between continuous and categorical variables was performed by logistic regression analysis with cytogenetic negativity as a dependent variable. Comparison between categorical variables was performed by the chi-square test. All analyses were done by means of SPSS 7.5 package software. A P value lower than 0.05 was considered significant.
Results
Haematological toxicity of mobilization chemotherapy
The median number of days with an absolute neutrophil count (ANC) Ͻ0.5 × 10 9 /l was 8.5 (range 3-19) days. Platelet counts Ͻ20 × 10 9 /l were present during a median (range) of 8 (3-18) days. A median (range) number of 18 platelet units (0-48) and 4 packed red blood cells (0-12) units were administered during pancytopenia. The median (range) number of days in hospital was 18 (4-50). Ten patients were managed in the Outpatient Department during the chemotherapy-induced pancytopenia; six of them had to be admitted to the hospital due to febrile neutropenia.
Nine patients (45%) did not develop febrile neutropenia. Eleven patients (55%) developed fever and positive blood cultures were isolated in five of them. One patient suffered from a dental infection during the febrile episode. No other infectious focus was observed during the neutropenic period. All infectious episodes resolved with broad-spectrum i.v. antibiotics without sequelae.
Non-haematological side-effects of mobilization therapy
The mini-ICE regimen was associated with mild-moderate extra-haematological toxicity. There was no grade 3-4 gastrointestinal toxicity. Sixteen patients (80%) did not develop mucositis, while three patients developed grade 1 and one patient grade 2 mucositis. Other side-effects after mini-ICE were fatigue, malaise and reversible alopecia. Side-effects did not limit PBPC collection in any patient. + cell count Ͼ2.5 × 10 3 /ml, and not the leukocyte count, the median (range) number of procedures per patient would have decreased to 2 (1-6) (P = 0.01). Moreover, correlation between circulating CD34 + cells (×10 3 /ml) and CD34 + cells collected in the apheresis bag the same day was very high Cytogenetic analysis from all the apheresis bags showed that four patients (20%) had complete Ph negativity in the collected products and nine patients (45%) had a partial negativity, with a final rate of major negativity of 65%. In three cases, there was a minimal negativity and in two, no negative cells. In two cases conventional cytogenetics were not performed: in both of them, molecular analysis by Southern blot gave a negative result, but the PCR was positive in all bags. In the four patients who achieved complete cytogenetic negativity in the apheresis products, molecular analysis by Southern blot was negative but PCR was positive in all of them. In two patients with partial negativity in all the aphereses performed, it was possible to select a Table 2 Characteristics and results of the aphereses procedures
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Mini-ICE -first apheresis (days) product suitable for an ASCT (у2.0 × 10 6 CD34 + cells/kg) with a complete negativity, thus making the percentage of patients with a completely cytogenetically negative product 30%.
The relationship between leukocyte counts and the percentage of Ph− metaphases in the aphereses bags is presented in Table 3 . We did not find significant differences between the percentage of apheresis products with major negativity collected with leukocyte counts у3.0 × 10 9 /l (n = 35) or Ͻ3.0 × 10 9 /l (n = 16) (60% vs 80%, P = 0.2). A logistic regression analysis was performed to analyse the possible impact of sex, age, Kantarjian stage at diagnosis and time between diagnosis and mobilization therapy on the achievement of major cytogenetic negativity. None of these factors significantly influenced the cytogenetic outcome.
Post-mobilization evolution
Six patients were autografted after 1 year on IFN-␣ due to absence of a cytogenetic response. At a median (range) time of 7.5 (3-16) months after transplantation, all of them remain in CP. Two additional patients who completed a 12 month course of IFN-␣ therapy without cytogenetic remission are in the program to be autografted shortly. One patient received an unrelated peripheral blood stem cell transplant and died due to cerebral toxoplasmosis 2 months after this procedure. The remaining 11 patients are within the first year of IFN-␣ treatment.
Discussion
Allogeneic marrow transplantation remains the only proven curative procedure for CML but it is only possible in a minority of patients. ASCT is being investigated as a therapeutic option for patients ineligible for allogeneic transplantation and not responding to IFN-␣. The role of ASCT in the management of CML is controversial with a number of trials and large-scale analyses of available data suggesting that it may extend CP and lead to a plateau in survival. 5, 21 Ph− progenitor cells can be collected from PB during the early phase of post-chemotherapy regeneration. 7, 8, 11, 12, 22 Optimal methods for Ph− PBPC mobilization in CML and timing of such procedures remain to be adequately defined. Acute leukaemia-based chemotherapy regimens (eg ICE protocol) were initially used for mobilization purposes in these patients. 7, 9, 12, 23 They allowed achievement of a significant proportion of Ph− cells in the apheresis products but these regimens were not devoid of significant procedure-related mortality (4-5%). [24] [25] [26] Whether patients with CML who are potential candidates for autologous transplantation should undergo PBPC mobilization at diagnosis or following a trial of IFN-␣ remains controversial. Carella et al 22 suggested that the best mobilization results are obtained in patients mobilized at diagnosis. This approach has to be balanced against the potential risks associated with early mobilization therapy, especially in the 20% of patients who might achieve a CCR with safe IFN-␣ therapy. The use of less intensive chemotherapy regimens for mobilization could overcome this problem. The mini-ICE regimen combines the same drugs as the ICE protocol at lower doses. In our experience with 20 consecutive CML patients at diagnosis, haematological toxicity and transfusion needs were significantly less than those reported with ICE therapy. This confirms the results obtained with the same protocol by the Genoa group. 13 It is noteworthy that nine patients (45%) in our series did not develop febrile neutropenia and that extra-haematological toxicity was almost absent. More important, there were no toxic deaths which contrasts with a 4-5% procedure-related mortality associated with more intensive regimens such as the ICE protocol. In all patients it was possible to collect the target of 2.0 × 10 6 /kg CD34 + cells for a future ASCT, after a median of 3 (1-7) aphereses per patient, a number lower than with the ICE regimen. 13 By contrast to our mini-ICE results, failures of mobilization therapy have been observed with the ICE regimen even in CML patients at diagnosis. 8, 22, 27 Although it has been claimed that high doses of chemotherapy are associated with best mobilizations, 12 severe and prolonged pancytopenias sometimes associate with slow haematological recovery and no CD34 + cells in the PB. Thirteen patients (65%) achieved major cytogenetic negativity in the apheresis products; this percentage is slightly inferior but not significantly different to the one reported by Carella et al 13 with the same regimen (80%). These authors did not find significant differences in rates of major negativity achieved with ICE therapy in a comparable historical control group of 17 CML patients. Although complete cytogenetic negativity was obtained in the collected products of four patients (20% of the series), molecular analysis by PCR demonstrated the presence of the bcr-abl transcript in all of them indicating the presence of 'minimal residual disease' in these products.
The optimal timing of the start of leukaphereses to optimise the harvesting of Ph− circulating stem cells is still a matter of controversy. Initial studies by the Genoa group suggested that there was a narrow window with leukocytes ranging between 1.0 × 10 9 /l and 3.5 × 10 9 /l when circulating hematopoiesis was predominantly Ph−. 6, 7 The recommendation was to start the aphereses with a leukocyte count of 1.0 × 10 9 /l, independent of the number of circulating CD34 + cells. Nevertheless, some authors suggest that the appearance of CD34 + cells in the PB coupled with a leukocyte count Ͼ1.0 × 10 9 /l gives the best indication of when to begin aphereses. 11 In our experience, the use of the level of leukocytes alone as a guide was inadequate. If aphereses had been initiated according to the number of circulating CD34
+ cells/ml, there would have been a significant reduction in the median number of aphereses performed per patient. Aphereses must be started with a circulating CD34
+ cell count Ͼ2.5 × 10 3 /ml, independent of the leukocyte count, and taking into account the fact that the cytogenetic negativity of the apheresis products did not correlate with PB leukocyte counts; the percentage of apheresis products with major negativity was not significantly different in those bags collected when the leukocyte count was above or below 3.0 × 10 9 /l. In conclusion, our experience indicates that the mini-ICE regimen can be safely administered to CML patients at diagnosis. The haematological and extra-haematological toxicities are low and a significant proportion of patients can be managed, at least partially, on an outpatient basis. The degree of cytogenetic negativity in the apheresis products compares with more intensive chemotherapy regimens. Finally, in our experience PB CD34 + cell monitoring should be used to determine the first day of collection.
